- Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine
- Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation
- The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications
Archives: PsychedelicNewsWire
Study Finds MDMA-Assisted Psychotherapy Improves Sleep in PTSD Patients
A new study has found that MDMA-assisted psychotherapy may improve sleep in PTSD patients. The study’s findings were reported in the “Journal of Traumatic Stress.”
Study author L. Jerome of the MAPS Public Benefit Corporation stated that the researchers were interested in learning whether MDMA-assisted therapy could decrease sleep difficulties in individuals with post-traumatic stress disorder and who suffer from disrupted sleep as a result…
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Founder of Synergy Soul to Headline at Meet Delic
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Brittany Hoogenboom will serve as a keynote speaker at Meet Delic on Nov. 7, 2021. Hoogenboom is the owner and founder of Synergy Soul, a brand focused on personal transformation through a holistic, integrated approach to life, business and wealth. She is also a certified physical therapy assistant, reiki master and yoga instructor. “We are very excited to have Brittany’s fresh voice and approach to personal transformation at Meet Delic,” said Delic co-founder, Jackee Stang. “She has a unique way of integrating health, wellness, spirituality and business, and I believe our attendees will gain valuable insight and knowledge from her experience.”
To view the full press release, visit https://ibn.fm/beBhS
About Delic Corp.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and the largest chain of psychedelic wellness clinics in the country with Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition). Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio
Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin’s research and development team has completed 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions. More than 50 novel compounds have been evaluated to date through collaborations with experienced contract research organizations for pharmacokinetic/pharmacodynamic profile, metabolic stability, receptor binding and safety to identify preferred candidates for further development. “Cybin continues to demonstrate superior properties of its CYB003 and CYB004 programs as we progress toward first in-human studies, expected in early 2022,” said Cybin CEO Doug Drysdale. “These experiments greatly expand our understanding of the potential therapeutic value of the studied compounds and further demonstrate Cybin’s strong research and development capabilities.”
To view the full press release, visit https://ibn.fm/YWoGa
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Another California City Approves Measure to Decriminalize Psychedelic Substances
Last week, the city council of Arcata, California, decriminalized psychedelic substances. The measure, which was approved in a unanimous vote, will make the distribution, growing and possession of entheogenic substances such as ayahuasca and psilocybin among the lowest law-enforcement priorities in the city. This is in addition to calling upon the district attorney of Humboldt County to consider the measure’s intent when deciding whether to prosecute individuals involved in the use of entheogenic fungi and plants. The initiative further states that driving under the influence as well as the manufacturing and commercial sale of psychedelic substances remains prohibited.
In an interview, Decriminalize Nature Humboldt lead organizer Danielle Daniel stated that the initiative represented a crucial point in history as it helped reclaim the people’s right to choose the path of healing they saw fit and explore their consciousness…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Leveraging Wide-Ranging Business, Eyeing Opportunity in Multibillion Industry
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is servicing the growing interest within the psychedelic drug market, projected to grow at a 12.36% CAGR from $4.75 billion in 2020 to $10.75 billion by 2027, through the expansion of its wide-ranging business. “Simultaneously and in line with its goal of enabling billions of people to live happier lives through the provision of psychedelic treatments, Delic has acquired Ketamine Infusion Centers, which operates two ketamine clinics located in Bakersfield, California, and Phoenix, Arizona, and recently announced its acquisition of Ketamine Wellness Centers, which currently operates 10 clinics across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington. Delic expects to open 15 additional clinics across the country over the next 18 months,” reads a recent article. “In recognition of the rapidly changing state of the industry, Delic has also focused its efforts around Delic Labs, a licensed cannabis and psilocybin research laboratory. It is the only Health Canada-licensed entity to exclusively focus on research and development of psilocybin vaporization technology.”
To view the full article, visit https://ibn.fm/9MnaK
About Delic Corp.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic, the premiere psychedelic wellness event, and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with University of Wisconsin Researchers for Clinical Pharmacology Studies Evaluating TRP-8803
- Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison
- The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation
- The partnership is the latest in a series of collaborations as the company prepares for Phase 2b trials
- Tryp intends to use data from its Phase 2a clinical studies, expected to launch this year, coupled with preclinical data and clinical pharmacology data for TRP-8803, to support the use of the novel drug formulation in Phase 2b trials
Why We Should Change How We View Psychedelic-Assisted Psychotherapy
Research on psychedelics began long before the substances were made illegal in the 1970s. When they were banned, the promising research on the substances ground to a halt — until recently. The current search for alternative and effective treatments for various mental health conditions has renewed interest in these substances, which have been used by different Indigenous communities for centuries.
Now, more people are opening up to the idea of psychedelic substances being used in combination with psychotherapy to treat mental health disorders…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – IBN and PsychedelicNewsWire to Heighten Visibility, Widen Reach of Upcoming Psychedelic Capital Conference
IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announced that it will collaborate with Microdose Psychedelic Insights, a cutting-edge media company aiming to move the psychedelics industry to the forefront of modern medicine, for its upcoming event. The Psychedelic Capital Conference, set to be held in an entirely virtual format on Oct. 28, 2021, will feature the most innovative and cutting-edge companies, latest IPOs, newest opportunities and deepest insights into the global psychedelic industry. The event will serve to educate attendees on the potential uses and benefits attached to psychedelics in today’s environment, from exploring ongoing governmental policy shifts to commercial product breakthroughs. Together with IBN, PsychedelicNewsWire (“PNW”), in its capacity as an official media sponsor, will further the distribution of content generated for the conference to enthusiasts within the psychedelics space. “IBN, alongside its PsychedelicNewsWire brand, is pleased to be collaborating once again with Microdose Psychedelic Insights,” said Jonathan Keim, communications director for IBN. “We will leverage our communications solutions to heighten visibility in advance of the event and also widen the reach to additional investor audiences through real-time coverage.”
To view the full press release, visit https://ibn.fm/UYEiH
About Microdose Psychedelic Insights
Microdose Psychedelic Insights is your guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, Microdose Psychedelic Insights distributes and creates the most compelling content, financial analysis, engaging events, and groundbreaking education to drive the psychedelics industry to the forefront of modern medicine. For more information, visit www.Microdose.buzz.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0 ) Announces Strategic Board Appointments of Distinguished Addiction Experts
Clearmind Medicine (CSE: CMND) (FSE: CWY0 ), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that professors Wim van den Brink and Gabriele Fischer have joined the company’s scientific advisory board. According to the update, van den Brink, M.D., Ph.D., is a professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam and a recognized expert in the neurobiology and pharmacological treatment of substance use disorders and behavioral addictions. Gabriele Fischer, M.D., is a professor of addiction research and treatment, medical director of the Addiction Clinic at the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, and has acted as principle or cooperating investigator on international epidemiological clinical and psychopharmacological studies in the field of substance use disorder and nonsubstance-related addictions. “Professor van den Brink and Professor Fischer have both made substantial contributions to the field of substance abuse and related behaviors, advancing the way we understand and treat addiction,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind, of the appointments. “There are few scientists in the world with their breadth of knowledge and experience, and we are delighted to welcome them to our scientific advisory board.”
To view the full press release, visit https://ibn.fm/lo09v
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY0. For more information about the company, visit www.ClearmindMedicine.com.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Included in AdvisorShares Psychedelics ETF
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced its inclusion in the AdvisorShares Psychedelics ETF (the “Fund”), currently trading under ticker symbol PSIL on the NYSE Arca exchange. According to the update, the Fund, launched in September 2021, is actively trading and focuses on companies that devote a majority of assets to psychedelic drug development. The Fund has built a portfolio including over 25 psychedelic companies. PSIL represents an exciting milestone for Tryp with the potential to bring a more diverse shareholder base and to broaden life science exposure for the company.
To view the full press release, visit https://ibn.fm/DW6sz
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Official Tells Legislators That VA Is Following Psychedelics Studies for Veterans
During a recent Congressional hearing, Rep. Colin Allred revealed that the Department of Veterans Affairs (“VA”) has closely been following studies on the therapeutic benefits of psychedelic substances such as MDMA for veterans. The meeting, which was held last month before the House Veterans’ Affairs Committee, focused on innovative approaches to deal with suicide prevention in veterans.
Officials had asked for an update on the study evaluating the use of psychedelic substances for the treatment of PTSD in military veterans, noting that there were good results from prior research on how psychedelic substances could help alleviate the mental health struggles of veterans…
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Collaboration to Provide Veterans with Free Ketamine Treatments
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced two new partnerships between Ketamine Wellness Centers LLC (“KWC”) and the Veterans Administration (“VA”) Community Care Networks of Illinois and Minnesota . According to the update, the nation’s largest chain of psychedelic wellness clinics, KWC, will offer ketamine treatments to veterans at no out-of-pocket cost at their locations in Naperville, Illinois, and Burnsville, Minnesota. The program is designed to cover patients experiencing post-traumatic stress disorder (“PTSD”), major depression and chronic pain who have exhausted all traditional medical treatments. “This partnership between KWC and the VA Community Care Network is a true game changer when it comes to the health and wellness of our veterans,” said Matt Stang, co-founder and CEO of Delic. “They face steep challenges when returning home, especially related to their mental and physical health, including PTSD, depression and pain. Now they can seek the treatment they need without worrying about whether they can afford it. These brave men and women have sacrificed so much to protect this country and we are honored to support them.”
To view the full press release, visit https://ibn.fm/d9cDq
About Delic Corp.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and the largest chain of psychedelic wellness clinics in the country with Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition). Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Seattle Decriminalizes Psychedelics, Becomes Largest American City to Do So
At the start of this week, the city council of Seattle approved a measure to decriminalize non-commercial activity of psychedelics, which includes the sharing and cultivation of substances such as mescaline that haven’t been derived from peyote, ibogaine, ayahuasca and magic mushrooms. This resolution extends the city’s already existing policy to not prosecute or arrest individuals for drug possession and protect the sharing and growing of psychedelic fungi and plants for personal growth, healing, spiritual or religious practices.
The measure, which was approved unanimously, stipulates that the arrest or prosecution of any person engaging in entheogen-related activities should be one of the city’s lowest enforcement priorities…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
New Hampshire’s Youngest Legislator Calls for Psilocybin Decriminalization
The New Hampshire state legislature is presently under Republican control, which has made it harder for legislators to end marijuana prohibition and establish a regulated sales system. Despite this, Rep. Tony Labranche, one of the youngest state lawmakers in the United States, is calling for the decriminalization of psilocybin and all illicit substances.
During an interview last week, the representative spoke about his plans to end the criminalization of individuals who possess or use psilocybin mushrooms in addition to generally decriminalizing the possession of controlled substances…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Delic Holdings (CSE: DELC) (OTCQB: DELCF) Reports Second Quarter Financial Results; Sets Up Business Pillars for Continued Growth
- Delic Holdings Corp. (the “company” or “Delic”) reported Q2 revenues of $149,290 while realizing a strong gross profit margin of 87%
- The company has recently broadened its business verticals through the acquisition of Homestead, a psychedelic media distributor, and Ketamine Infusion Centers LLC, one of the largest chains of ketamine clinics in the U.S.
PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Duncan Trussell to Keynote at Meet Delic: The World’s Premiere Psychedelic and Wellness Event
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Duncan Trussell will serve as a keynote speaker at Meet Delic on Nov. 6, 2021. An actor and stand-up comedian, Trussell co-created and appears in the Netflix animated series “The Midnight Gospel” and regularly travels the country performing comedy at festivals and shows. He also hosts the “Duncan Trussell Family Hour” podcast. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business with like-minded visionaries. Trussell’s keynote will be a live taping of his podcast, a weekly salon-style supershow, ranked as one of the top 25 comedy Apple Podcasts, where he and his guests explore the outer reaches of the multiverse. “Duncan is one of those special people who has many talents and excels at all of them,” said Jackee Stang, Delic co-founder. “We are honored and excited to have him host his popular podcast live from the conference so attendees can join in on the fun!”
To view the full press release, visit https://ibn.fm/fPXnl
About Delic Corp.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and the largest chain of psychedelic wellness clinics in the country with Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition). Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief Financial Officer Luke Hayes will provide a live overview of the company’s activities and elaborate on how Tryp is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. Interested parties should visit https://ibn.fm/1Y2RX to register for the conference and access the presentations.
To view the full press release, visit https://ibn.fm/TWdb3
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio
Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. According to the update, the application, governed by the Patent Cooperation Treaty (“PCT”), brings the potential to obtain patent coverage in 153 countries. “The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches,” said Doug Drysdale, the company’s CEO. “Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health conditions.”
To view the full press release, visit https://ibn.fm/WgqaY
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and potential treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://ibn.fm/NCORl). “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reads a recent article quoting a Yale Daily News publication titled “Yale Researchers Discover Healing Effects of Psychedelic Drug.” In the piece published in the Neuron journal, researchers at the Yale School of Medicine “presented evidence that administering this drug to mice resulted in an approximately 10% increase in neuron size and density in the frontal cortex of the brain. Led by postdoctoral associate Lingxiao Shao and associate professor of psychiatry and neuroscience Alex Kwan, the team found that this ‘structural remodeling’ occurred within 24 hours of the drug administration and persisted for one month, indicating that psilocybin made long-lasting changes in the brain.” Studies such as this serve to validate and strengthen the work done by Cybin, which is on a mission to revolutionize mental health care.
To view the full article, visit https://ibn.fm/ojHKr
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Elon Musk Acknowledges Potential of Psychedelic Substances at CodeCon
During an interview at CodeCon 21, Elon Musk stated that individuals should be open to psychedelic substances. The tech-development event was hosted by Field Trip Health’s executive chairman, Ronan Levy, who asked Musk about whether he supported the use of psychedelic substances for therapeutic purposes.
Levy asked Musk about the role psychedelics could play in addressing some of the society’s destructive tendencies, with Musk replying that while most of individuals who were making laws currently were from a different era, there would be greater receptivity to the substances’ benefits…
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources
- Tryp Therapeutics recently launched a new website with updated resources to be featured on the site
- Over the next few weeks, the company will share key resources that will be the standout features of the new website
- Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions
- Cybin names Dr. Amir Inamdar as chief medical officer for European operations
- The company appoints Dr. Geoff Varty as head of research and development
- Both professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics
Psychedelic Substances May Decrease Shame Among Individuals Who Suffered Mistreatment as Children
A new study, reported in the “Chronic Stress” journal, has found that the use of psychedelic substances is linked to decreased levels of internalized shame and PTSD symptoms in adults who underwent maltreatment as children.
The author of the study, CJ Healy, who is a PhD student at the New School for Social Research, stated that while there existed various studies on the therapeutic effects of psychedelics, very few looked into the substances’ potential use in nonclinical settings. Healy explained that most individuals across the globe who were using psychedelics to heal themselves were taking the them in nonclinical settings, either at a rave, at home or with friends, which is why it made sense to conduct research…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) Engages Clinipace in Pursuit of FDA Approval for Therapeutics
Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced a strategic partnership. Clearmind has engaged Clinipace Incorporated, a full-service contract research organization (“CRO”), to advise the company in its pursuit of Food and Drug Administration (“FDA”) approval for its therapeutics. “Moving any drug through the FDA approval process requires deep expertise and meticulous attention to detail; this is particularly true for psychedelics,” said Adi Zuloff-Shani, PhD., CEO of Clearmind. “We chose Clinipace as our CRO as they have facilitated dozens of successful regulatory submissions operating at the highest clinical and ethical standards.”
To view the full press release, visit https://ibn.fm/mq5Wo
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY0. For more information about the company, visit www.ClearmindMedicine.com.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Collaboration with University of Wisconsin Researchers to Evaluate TRP-8803
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, this morning announced a collaboration to support clinical pharmacology studies for Tryp’s proprietary drug product TRP-8803. Dr. Paul Hutson, Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy and Dr. Christopher Nicholas, Assistant Professor at the University of Wisconsin School of Medicine, will serve as investigators on the clinical pharmacology studies to assess the pharmacokinetics and safety of TRP-8803 in healthy, volunteer patients. The completion of the studies is anticipated to deliver additional regulatory support for TRP-8803. “We are fortunate to benefit from Dr. Hutson’s and Dr. Nicholas’s tremendous expertise in psilocybin-based treatments and their effects on patients,” Tryp Therapeutics President and Chief Scientific Officer Jim Gilligan, PhD stated in the news release. “TRP-8803 has the potential to set the standard in safety, control, and patient comfort for psilocybin-based therapies. We look forward to working with Dr. Hutson and Dr. Nicholas on this exciting endeavor.”
To view the full press release, visit https://ibn.fm/9t8l4
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Grand Rapids City Council Approves Psychedelics Decriminalization Measure
Earlier last week, another city in the state of Michigan passed a measure that called for the decriminalization of psychedelics, including ayahuasca and psilocybin. The measure doesn’t meet activists’ expectations, however, because it doesn’t change any enforcement practices in the city. Instead, the initiative stipulates that the city commission and mayor support federal, state and local legislative efforts to decriminalize entheogenic fungi and plants as well as plant-based compounds that are classified under the Controlled Substances Act.
The measure, which the city commission of Grand Rapids approved in a 5 to 2 vote, states that individuals who seek to improve their well-being and health through the use of entheogenic fungi and plants should have the freedom to do so without risk…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Former Congresswoman Backs the Use of Psilocybin in Treating Alcohol Use Disorder
Former Congresswoman Mimi Walters (R) has been proclaiming the therapeutic benefits of psychedelic substances. In a recent interview, Walters revealed that somebody close to her family had been struggling to overcome alcohol use disorder while she talked about a legislation that would legalize the possession of various psychedelics.
The former Republican congresswoman, who left Congress in 2019, explained that the close family friend had been able to recover from the disorder with the help of psilocybin after participating…
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs Moves Forward with Strategic Steps toward Commercialization
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Delic Labs, which is part of the Delic Corp. family, has applied for a Health Canada 56 Research Exemption. Approval of the application allows Delic Labs scientists to perform research and tests on compounds in addition to psychedelic mushrooms, which it currently holds a 56 research exemption to study. The new application would allow the lab to study substances such as MDMA and LSD. The lab has also submitted an application for a dealer’s license. These steps are part of a strategic plan leading toward eventual commercialization of the lab’s psilocybin research and associated intellectual property (“IP”) for medical and research purposes. A federally authorized psilocybin and cannabis research laboratory, Delic Labs is focused on extraction, analytical testing and chemical process development. The facility conducts research designed to enable Delic Holdings to develop innovative product lines and intellectual property. Currently research includes psilocybin vaporization technology that has the potential for distribution across the company’s physical footprint and licensed psychedelic wellness clinics in the United States. The lab is also a leading cannabis analytical and research company with clients that include some of the largest brands in the world. “Never before has a lab been authorized to test psychedelic compounds such as MDMA and LSD with the opportunity to create new medicines for the millions suffering from debilitating conditions like depression, anxiety, PTSD and Parkinson’s disease,” said Delic Corp. cofounder and CEO Matt Stang in the press release. “Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market.”
To view the full press release, visit https://ibn.fm/8QCCD
About Delic Corp Inc.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms such as Reality Sandwich; Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
What Investors Consider Before Investing in Psychedelic Startup Companies
In the last few years, venture-capital funds have played a big role in facilitating the establishment of psychedelic firms. To do this, those VC companies have had to go through many business models and pitches.
Research shows that the top investors in the psychedelics industry since the beginning of last year are Neo Kuma, Palo Santo and Noetic Fund…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced the keynote speaker for its upcoming Meet Delic event, a revolutionary, two-day immersive edutainment experience designed to bring together the world’s leading psychedelic and wellness thought and business leaders. Dr. Molly Maloof, MD, will speak at the premiere event, which will take place on Nov. 6, 2021. Maloof has an impressive background of working with investors, entrepreneurs, and executives to optimize their health. She has also consulted with an estimated 45 companies that operate in the digital health, consumer health and biotechnology industries. Cofounder of the Psychedelic Clubhouse on the Clubhouse app, she has earned a stellar reputation for her insight and experience in clinical strategy, product development, clinical research and scientific marketing. In her keynote address, titled “Aphrodisiacs and Psychedelics: A History of Medicine for Love,” Maloof will discuss psychedelic aphrodisiacs as well as historical, modern-day and future contexts for the role of psychedelics in human relationships. The event agenda also includes an array of panels and presentations focusing on psychedelics; musical and entertainment acts will be highlights of the event’s evening activities. Meet Delic is designed to increase awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community. “Molly has deep experience in the space where health, wellness, technology and business intersect,” said Delic cofounder Jackee Stang in the press release. “Her entrepreneurial spirit drives her to create new channels for people to learn about optimizing their health and wellness, and we are happy to have Molly speak at Meet Delic.”
To view the full press release, visit https://ibn.fm/Od3uV
About Delic Corp Inc.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms such as Reality Sandwich; Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
NIDA Awards Grant for Research on Potential of Psilocybin in Treating Cigarette Addiction
The National Institute on Drug Abuse is financing research on the use of magic mushrooms in managing cigarette addiction. The top federal drug agency recently awarded the grant to researchers from the University of Alabama at Birmingham, New York University and Johns Hopkins University to investigate how psilocybin could help individuals quit smoking cigarettes.
Last week, Matthew Johnson, a professor at Johns Hopkins University, revealed that the researchers had been awarded the grant, noting that he believed that it was the first grant from the federal government in more than five decades to directly study the therapeutic benefits of a classic psychedelic…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Researchers Develop Statistical Model That Can Characterize Ketamine’s Effects on the Brain
Researchers from the Massachusetts General Hospital and the Picower Institute for Learning and Memory at MIT have developed a statistical model that can characterize how ketamine affects an individual’s brain. The research, which was published in “PLOS Computational Biology,” found that ketamine produced different effects, which means that to improve patient outcomes and better understand ketamine, a ketamine-specific model was needed.
This is why the researchers designed a model based on rhythm measurements from two animal subjects and nine human subjects…
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty as the new head of research & development. In addition, the company has made some internal promotions, naming Lori Challenger as chief compliance, ethics & administrative officer and Robert Mino as general counsel. A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug-development experience, Inamdar has deep expertise in progressing numerous drugs from preclinical development through to early phase clinical trials, including designing and successfully delivering proof-of-concept studies. Varty has established a reputation as a highly experienced neuroscientist and drug discoverer with a track record of progressing novel molecular entities into clinical trials, and ultimately, to the patient. In addition, Cybin announced that it is partnering with ROK Consulting Inc., a leading investor communications and public relations company. ROK will assist Cybin in strenthening its market awareness, communications strategy, and engagement with leading financial and institutional market participants.
To view the full press release, visit https://ibn.fm/MLtfJ
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Phantom Limb Pain: Causes and How a Physical Therapist May Help
When an individual’s leg or arm is traumatically lost or surgically amputated, they may experience a persistent sensation indicating that the lost limb is still present. This phantom sensation, which may be unpleasant or painful, is commonly called phantom limb pain. Estimates show that while about 80% of individuals who have undergone amputations will experience this type of pain, the pain persists only about 20% of the time, with some of these individuals experiencing this pain even two years after the amputation procedure.
While it doesn’t result from conditions such as depression and psychiatric stress, phantom limb pain may be influenced by these circumstances because it has been linked to the nervous system and the brain…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Enters First-of-Its-Kind Partnership with Paradigm Healthcare
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced a first-of-its-kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC”). Under the partnership, KIC will have access to Paradigm’s Benchmark UDT(TM) toxicology solution that utilizes LC/MS/MS test methods to identify and accurately measure drug compounds in the body, ensuring the highest quality toxicology results and clinically relevant test data to support medical decision making. “Paradigm’s Benchmark testing platform brings state-of-the-art drug testing technology and new reporting tools to clinicians who use psychedelics to treat people with serious behavioral health conditions,” said Matt Stang, founder and CEO of DELIC. “We are proud to partner with Paradigm. By integrating their state-of-the-art testing capabilities, KIC will be able to provide patients suffering from depression, anxiety, PTSD and other debilitating conditions the most accurate, personalized ketamine treatment protocol in the industry.”
To view the full press release, visit https://ibn.fm/wkayL
About Delic Corp.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial
- Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study
- The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients
- According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months
- Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803
Why Nuanced Approach in Dealing with Mental Health Issues, Specifically Depression, Is Important
A couple of decades ago, talking about mental health issues in the public was an unspoken taboo. Research on mental health conditions hadn’t come as far as today, and society’s view of mental health wasn’t as open, which led to many people suffering in silence, scared to speak up or seek help. Today discussing how conditions are approached and treated is much more open.
Among the most common mental health conditions is depression, a serious ailment that negatively affects how an individual feels, acts and thinks…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Spiritual Emergencies and Psychedelics: What Are They About?
In the last few years, we’ve seen an increase in the interest in the therapeutic potential of psychedelics, in both nonclinical and clinical settings. Psychedelic substances such as LSD and psilocybin mushrooms possess the ability to cause huge shifts in an individual’s perception and understanding of reality. While seeing things in the world in a new light may be good for an individual’s psyche, it may also trigger psychological distress referred to as a spiritual emergency.
What is a spiritual emergency?
This refers to a transformative or spiritual crisis in which a person may move toward a greater state of wholeness and integration…
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Meet Delic to Showcase Lamar Odom’s Path to Healing with Psychedelics
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on Nov. 7, 2021. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers that earned him 2009 and 2010 NBA championships. Odom joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the gold-winning U.S. men’s basketball team at the 2004 Athens Olympics. In 2015, Odom was hospitalized in Las Vegas after a near-death overdose resulting in multiple seizures, strokes and a coma. An upcoming documentary chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwork. His keynote “Fireside Chat: Lamar Odom & Zappy Zapolin: Reborn” will reunite Odom with the documentary’s director for an intimate discussion of his healing journey with psychedelic medicine. “We’re so honored Lamar will be sharing his personal story of healing with all of us at Meet Delic,” said Jackee Stang, co-founder of Delic. “He has shown tremendous courage facing his past traumas and addiction, and his openness to exploring psychedelic treatments is inspiring. We hope his story will open the hearts and minds of more people so we can truly address the growing mental health crisis we’re facing.”
To view the full press release, visit https://ibn.fm/1yQoT
About Delic Corp.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Mental Health Treatment Innovation
- WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19
- People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infection
- Cybin is on a mission to revolutionize mental healthcare
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Looks Optimally Positioned to Benefit From Continued Growth Within the Psychedelic Wellness Sector
- Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector
- Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US
- The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough therapy” status in 2018
- Denver and Oakland have been among the first US cities to decriminalize the use of psilocybin mushrooms with California currently studying whether to follow suit
- The psychedelic drugs market is expected to reach a size of $10.75 billion by 2027
Congress to Vote on Psychedelics Research Amendments for Active Military Members
As is so often the case, legislators have introduced various amendments to upcoming legislation for active military members. Those include measures to protect banks that offer their services to state-legal cannabis businesses and those that will facilitate research on the benefits of psychedelics for military personnel.
The measure that would enable the defense secretary to award grants for research into the therapeutic potential of psychedelics such as ibogaine, psilocybin and MDMA for military members with PTSD, was filed by Rep. Dan Crenshaw…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Congress to Vote on Psychedelics Research Amendments for Active Military Members
As is so often the case, legislators have introduced various amendments to upcoming legislation for active military members. Those include measures to protect banks that offer their services to state-legal cannabis businesses and those that will facilitate research on the benefits of psychedelics for military personnel.
The measure that would enable the defense secretary to award grants for research into the therapeutic potential of psychedelics such as ibogaine, psilocybin and MDMA for military members with PTSD, was filed by Rep. Dan Crenshaw. The grants will be awarded to not-for-profit organizations, academic institutions, and state or federal agencies. Under the measure, researchers would be required to carry out clinical trials on PTSD treatments, which would involve either group or individual therapy.
The grants would also be utilized in the support of training practitioners treating military members who are eligible to use psychedelic substances.
Thus far, Crenshaw, who is also a veteran, had voted against drug policy and cannabis reform measures. This includes previous amendments that would have removed barriers to research on the medical benefits of psychedelic substances. It is worth nothing that the congressman’s home state Texas recently passed a law that required officials to conduct research on the potential benefits of ketamine, MDMA and psilocybin for military veterans.
A bipartisan list of co-sponsors, including Rep. Ed Perlmutter, are also working on attaching language to the National Defense Authorization Act that would hinder financial regulators from imposing penalties on credit unions or banks that service state-legal cannabis businesses. Perlmutter is the sponsor of the SAFE Banking Act, which is similar to this amendment and was approved in the House.
Despite the measure not being directly linked to issues related to defense, Perlmutter views the sure-to-pass National Defense Authorization Act as a vehicle for the reform that may proceed to the Senate. This is because all marijuana banking legislations that were approved in the House have yet to be advanced to the Senate.
Rep. Lou Correa also proposed amendments on cannabis research that would require the head of the Veterans Affairs to conduct a clinical trial into the effects of medical marijuana on the health outcomes of veterans who have been diagnosed with PTSD or who deal with chronic pain. With regard to chronic pain, the double-blind randomized controlled trial would explore the effect of the use of marijuana on neuropathic pain, and the dosage and use of alcohol, benzodiazepines and opioids, after taking into consideration overall factors including anxiety and sleep.
For post-traumatic stress disorder, the researchers would be required to study the impact of cannabis on the use of benzodiazepines and overall symptoms.
The attempts to put in place appropriate laws governing psychedelic research come at a time when a number of companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) have taken significant steps towards advancing psychedelic drug-development programs, and such efforts will add impetus to other researchers seeking a greater understanding of these promising compounds.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits in the brain. Specifically, Tryp is bringing light to psilocybin usage in diseases with high unmet needs, including chronic pain, through its Psilocybin-For Neuropsychiatric Disorders (TM) (“PFN”) program. “With its three strategic initiatives — develop, protect and monetize — Tryp remains committed to utilizing FDA’s 505(b) (2) regulatory pathway with available third-party preclinical data to not only shorten the approval timelines but also lower the cost of development programs,” reads a recent article. “This is in a bid to bring psychedelic treatments closer to the people. It also seeks to grow an industry that has been dormant for decades for all the wrong reasons.”
To view the full article, visit https://ibn.fm/yh7Tj
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Garners Attention as ‘Emerging Leader in the Psychedelic Therapeutics Space’
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its Q1 2021 operational and financial report for the period ended June 30, 2021. The biotech company hit several milestones, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than CA$120 million. In addition, Cybin has started the next phase of its digital therapeutics platform, signed an exclusive R&D collaboration agreement with TMS NeuroHealth Centers Inc to establish Mental Health Centers of Excellence, as well as commenced scaling up its European operations and research activities with several academic and clinical research organizations. A recent article quotes Cybin CEO Doug Drysdale as saying, “During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space. We believe the molecules we have under development may have the potential to transform the treatment landscape and fill current unmet treatment needs for various psychiatric and neurological conditions.”
To view the full article, visit https://ibn.fm/QUdnh
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
California Activists Receive Approval to Gather Signatures for Psilocybin Legalization Measure
Activists in the state of California have received approval to start gathering signatures for a measure to legalize magic mushrooms. Last week, the office of the attorney general released a title and summary for the initiative, which activists are hoping to include in next year’s ballot.
The group behind the proposal, Decriminalize California, is now focused on collecting 623,212 signatures that will allow the initiative, which would legalize the sale of psilocybin under California state law to make the ballot…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates
- Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes
- The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan
- Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit
- The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow next year
Researchers Focus on Better Understanding Ketamine’s Mechanism of Action
Ketamine has been used for years as an anesthetic and as a horse sedative. In the early 2000s, researchers discovered that the psychedelic possessed antidepressant properties. This finding prompted research into the medication, with the U.S. FDA recently approving a ketamine-based nasal spray indicated for the management of depression.
During the 2021 Festival of Neuroscience at the British Neuroscience Association, a whole session was devoted to talks on new research on understanding the substance’s mechanism of action and its possible use as an alcohol use disorder treatment...
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of the drug product as well as the protocol for the study. Tryp anticipates starting the study later this year if approved by the FDA. “This IND submission marks the most important milestone the company has achieved to date and will be critical in identifying patient responses to the active ingredient, consistent with that of our proprietary drug candidate, TRP-8803, that will be used in Phase 2b trials and beyond,” said Tryp Therapeutics CEO and chair Greg McKee in the press release. “This is the first of several IND filings we expect to make in the coming months in support of our work to address various chronic pain and eating disorder indications, and we are eager to begin enrolling our first patients in multiple Phase 2a trials later this year.”
To view the full release, visit https://ibn.fm/k7nhi
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Canadian Company Takes Advantage of Psychedelics Popularity with Their New Beverage
Psychedelic Water is focused on capitalizing on the popularity of psychedelics with its kava-based drink. Kava is popular in the South Pacific, particularly in Fiji, which has it as its national drink. The Canadian beverage company asserts that its Psychedelic Water beverage is the first psychedelic blend of green tea leaf extract, damiana leaf and kava root in the world.
The beverage isn’t hallucinogenic and has been developed to produce a calming sensation for a mood-boosting experience…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Study Finds Intravenous Ketamine May Be Safely Used for Depression in Adolescents
A study has found that intravenous ketamine is effective in reducing symptoms of depression in the short term and is well tolerated among adolescents suffering from depression. Yale Child Study Center’s Jennifer B. Dwyer and her fellow researchers stated that case reports proposed early potential effectiveness of intranasal ketamine in bipolar depression and intravenous ketamine in depression in adolescents.
The researchers also revealed that an intravenous (“IV”) ketamine open-label trial that was conducted recently, which recruited 13 adolescents with treatment-resistant depression, also proposed that ketamine could be efficacious in this population…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Study Finds Way to Explain LSD’s Potency
LSD is among the most potent and longest-lasting psychedelic substances. Until recently, scientists hadn’t fully understood why LSD’s effects lingered for more than 12 hours. However, a study has found that how the drug fits into brain receptors can help explain the drug’s longevity. The study was published in “Cell.”
The study’s senior co-author Bryan Roth stated that many individuals who ingested LSD weren’t aware of how long its effects would last…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to open 15 additional clinics in the next 18 months. KWC’s ketamine infusion treatment clinics are located in Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington; Delic’s clinics are in California and Arizona. “This is a game changer for the future of health and psychedelic wellness in America,” said Delic cofounder and CEO Matt Stang in the press release. “We will be able to bring the highest-quality and safest treatment options to tens of millions of Americans suffering from a range of pain and mental health conditions. KWC is the leading and largest network of trusted health clinics operating in our space, and we have architected Delic to scale their efforts and contribute to their position through our existing portfolio of clinics and media properties which can drive patient count and demand. KWC brings a world-class management team to the Delic family with decades of experience in operating clinics and hospitals and have had incredible success in their treatment outcomes for patients. Adding KWC will ensure our existing patients and many more in the future will receive the best medical treatment and care. We are thrilled to partner with KWC and bring accessibility and psychedelic wellness to millions today through ketamine infusions and in the near future through all FDA-approved treatment options, which we expect to include MDMA and psilocybin.”
To view the full press release, visit https://ibn.fm/G5DBf
About Delic Holdings Inc.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms such as Reality Sandwich; Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Vistra Energy Concludes Expansion at Largest Battery Storage System in California
The Moss Landing battery system expansion project, dubbed the BESS project, has been concluded. At phase 1, the storage facility reached 1,200 MWh and now with the completion of phase 2, the facility is at 1,600 MWh.
Vistra Energy, a power-generation company, brought this project online last year in December at a site that was previously occupied by natural gas turbines at its power plant in the Monterey County, California.
NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies Inc. are available in the company’s newsroom at https://ibn.fm/StorEn
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
[email protected]
MiningNewsWire is part of the InvestorBrandNetwork.
Study Finds Ketamine Safe for Use in Managing Treatment-Resistant Depression
New research conducted by researchers from the Federal University of Bahia has found that ketamine and esketamine may be used safely as a treatment for depression. Ketamine is a synthetic compound used as an anesthesia drug while esketamine is an anesthetic that has been used to manage treatment-resistant depression. Ketamine is sometimes abused as a club drug and is popularly referred to as Special K and K in this scenario.
Various studies suggest that low doses of ketamine offer rapid antidepressant effects, improving a patient’s mood within 24 hours…
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)
- Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate
- The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns
- Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan
- The DEA recently recommended a significant increase in cannabis and psilocybin use in medical science research, and the White House has asked Congress to consider changing drug legislation to better address the use of those drugs in clinical research
Researchers Find That Encounters with ‘Higher Power’ May Improve Mental Health
Over the millennia, different individuals have admitted to experiencing deeply moving religious encounters, sometimes spontaneously and sometimes while under the influence of psychedelics, including ayahuasca or psilocybin. Researchers at Johns Hopkins Medicine recently conducted a survey involving individuals who had admitted to experiencing personal encounters with a higher power.
The survey results indicated that more than half of the individuals who identified as atheists stopped identifying as such so after their experience, regardless of whether it was brought on while under the influence of a psychedelic or if it was spontaneous…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Participation in Oppenheimer Fall Healthcare Summit
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, will be a featured presenter at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The three-day event, scheduled for Sept. 20–23, 2021, will be a virtual event. Tryp CEO and chair Greg McKee will be part of the agenda with a company presentation slated to begin on Sept. 21 at 3:35 p.m EDT. The presentation will include a company overview as well as a discussion about Tryp’s pipeline as well as its for psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”) program for chronic pain and other indications.
To view the full release, visit https://ibn.fm/JMUJl
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Oregon Psilocybin Panel Joins Harvard to Study Psychedelic History
Researchers cleared by the Oregon Psilocybin Advisory Board will be working with Harvard Law School to study the culture and history of psychedelics. The aim of this new research project is to help inform legislative efforts in other states where psychedelics reform is being pursued.
In an interview, Mason Marks, director of Harvard’s Psychedelics Policy Center, stated that Oregon was one of the few states exploring the regulation of psilocybin services, adding that the project would help inform decision making. Marks is also a member…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Recent Acquisition Boosting Psychedelic Drug Development Program
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, announced its most recent acquisition and wholly controlled subsidiary, Adelia Therapeutics Inc., is already reporting success, having achieved certain milestones for the year. Cybin closed on the acquisition of Adelia late last year, with the company noting several key advantages gained through the transaction. According to a recent article, Cybin CEO Doug Drysdale stated that the company sees “this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s expertise across multiple molecules and multiple indications could potentially give Cybin the ability to address gaps across a larger domain.” Since the acquisition, both Cybin and Adelia “have been focused on a three-pillar development strategy, including a novel discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; efficient drug delivery to enhance dosing control; and a potential novel treatment regimen.”
To view the full article, visit https://ibn.fm/4BWCH
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments
- Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression
- Administering drug to mice resulted in an approximately 10% increase in neuron size and density
- Cybin is focused on progressing psychedelic therapeutics
Michigan Senators Introduce Bill to Legalize Cultivation, Possession of Psychedelic Substances
Last week, senators in the state of Michigan introduced a piece of legislation that would legalize the possession, growing and delivery of various fungi- and plant-derived psychedelics, including mescaline and psilocybin.
The bill, which was sponsored by Senators Adam Hollier and Jeff Arwin, would alter state statutes to exempt individuals from criminal penalties for such activities, as long as they weren’t receiving valuable consideration, cash as money for the entheogenic fungi and/or plants. This is because commercial…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook
- So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space
- The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders
- Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida
- The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors
Biden Administration Streamlines Registration Processes for Research on Schedule I Substances
Last week, the White House Office of National Drug Control Policy recommended that a modification be made to the federal drug scheduling system in an effort to simplify the process of conducting studies on schedule I substances, which include cannabis and psychedelics like psilocybin.
In a letter to Congressional leaders, the ONDCP stated that it wanted to encourage research on the substances by streamlining the registration process for researchers to access Schedule I drugs. This move is part of an extensive initiative to develop a strategy to decrease the supply of illicit fentanyl while diminishing barriers to scientific research on schedule I drugs and protecting…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
DEA to Increase Psilocybin, Cannabis Production for Research Purposes
The United States Drug Enforcement Administration (“DEA”) has proposed an increase in the manufacture of cannabis, cannabis extract, psilocin and psilocybin for clinical trial and research purposes. In its most recent notice, the DEA stated that its objective was to assist in the development of new federally approved therapies.
The DEA stated that it believes in supporting the regulated research of controlled substances classified under Schedule I of the Controlled Substances Act...
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference
- Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021
- Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program
- Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13
- Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases with high unmet medical needs, such as chronic pain conditions and eating disorders
Study Finds That Ayahuasca May Enhance Self-Perception of Patients with Social Anxiety Disorder
A study that was recently published in the “Journal of Clinical Psychopharmacology” has found that ayahuasca could enhance the self-perception of individuals with social anxiety disorder. Ayahuasca is a psychedelic brew that has been used for hundreds of years by indigenous tribes in the Amazon. It contains monoamine oxidase inhibitors and DMT (dimethyltryptamine), another potent psychedelic. Preliminary studies have provided evidence suggesting that ayahuasca is psychologically beneficial to individuals who suffer from depression and anxiety.
Rafael Guimarães dos Santos, the study’s author, states that social anxiety disorder is an under-diagnosed and prevalent disorder with limited treatment options…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Share Company’s Mission, iSTRYM Developments at 2021 SANA Symposium
MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced its presence at the 2021 SANA Symposium as a platinum sponsor and host of the Innovation Theater. According to the update, MINDCURE will be engaging with clinicians around the world interested in learning more about psychedelic-assisted psychotherapy, and specifically in adopting novel protocols and practice standards around psychedelics. The timing of the conference coincides with the company’s recent release of its digital therapeutics (“DTx”) platform for psychedelics — iSTRYM — into partner clinics across North America. “We could not ask for a better time or a better forum to share our company’s mission, and specifically our developments around iSTRYM, with an engaged and educated audience with a particular interest in psychedelics and psychedelic-assisted psychotherapy,” said Kelsey Ramsden, president and CEO of MINDCURE.
To view the full press release, visit https://ibn.fm/ZI0PH
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Why Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is committed to bringing science-backed benefits to all and reframing the psychedelic conversation. “The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the first psychedelic umbrella platform. It is currently a trusted source for those interested in psychedelic culture, education, treatments and more,” reads a recent article discussing Delic’s positioning. “While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized), and large-scale production and brings them under its big tent of resources and reach.”
To view the full article, visit https://ibn.fm/nHMnp
About Delic Corp.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic, the premiere psychedelic wellness event, and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network with a mission to provide education, research, high-quality products and treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Newfoundland Women Report Using Psychedelics Medicinally and Hope for Legalization
Researchers have found that psilocybin, which is the hallucinogenic compound found in so-called magic mushrooms, has shown potential in treating various mental conditions, including anxiety, major depressive disorder and addiction.
A woman in Newfoundland who was diagnosed with severe PTSD revealed that psilocybin helped get her life back…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders
- Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs
- The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy
- Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible experience
- Investment banking services provider, Ladenburg Thalmann & Co., announced on Aug. 26 that it has initiated coverage on Tryp with a “buy” rating
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level. A recent article reads, “Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also acknowledged that psychedelics are far from mainstream, but that is an opportunity for the company to play the role of a first mover. ‘They [psychedelics] are not mainstream yet. That’s actually the opportunity. Nobody’s done that yet. We’re just now making them synthetically and making them up to pharmaceutical-grade standards,’ Mr. McKee noted.”
To view the full article, visit https://ibn.fm/crzSJ
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Not-for-Profit Organization Urges Health Canada to End Psilocybin Mushroom Prohibition
TheraPsil is urging Health Canada to end the five-decade prohibition against the possession of psilocybin mushrooms and the psychedelics these entheogenic fungi produce. The not-for-profit organization, which advocates for the therapeutic use of psilocybin, has spent months drawing up proposed legalization measures for these mushrooms based on the same regulations the federal government created for medical marijuana two decades ago.
Spencer Hawkswell, CEO of the British, Columbia-based organization stated that TheraPsil had sent a proposal to Jennifer Saxe, who is the director general of Health Canada…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Bill to Legalize Psychedelics Possession in California Paused
A measure to legalize the possession of psychedelics such as ayahuasca and psilocybin in the state of California will not be advancing this session. The temporary halt to the bill occured after its sponsor decided that more time was needed to compile additional evidence for reform in order to solidify the bill’s chances of being passed. The bill, which had already been cleared in the Senate, will be made into a two-year legislation, which means it will not be advanced to the floor until 2022.
The legislation was sponsored by Sen. Scott Wiener, who has spent a lot of time garnering support for reform, including holding a rally with health officials, law enforcement and military veterans recently…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities in places outside the mainstream. “Cybin (NYSE: CYBN) is a biotech that’s developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in ‘magic mushrooms’). Based on a swath of extremely positive coverage in the scientific literature, I’m of the opinion that these psychedelic therapies are going to be a tremendous force for good — and investor returns — over the coming years. And Cybin could well be one of the leaders in the psychedelics space, so let’s take a look at why it’s shaping up to be a brilliant investment,” reads the article. “Cybin has a few technologies that will give it an edge in the market for psychedelics, assuming it eventually gets a drug approved for sale.”
To view the full article, visit https://ibn.fm/ZNxec
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Grand Rapids One Step Closer to Decriminalizing Entheogenic Plants, Fungi
The city of Grand Rapids, Michigan, may soon deprioritize the enforcement of laws against the use, growing and possession of entheogenic fungi and plants. Grand Rapids city commissioner Kurt Reppart stated that, while this wouldn’t decriminalize the psychedelics, it would allow individuals to gift, grow, use or possess psychedelics without facing any legal charges.
Reppart is in favor of making psychedelics the lowest priority for the city’s law enforcement and believes that the move will not only acknowledge that these fungi and plants can not only be medicines for individuals using them to treat conditions such as anxiety, depression, addiction and PTSD, but that they also save resources…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Filmmaker Behind Netflix’s Psychedelics Documentary Is Working on Sequel
If you’re interested in psychedelics and have watched the “Adventures in Psychedelics” documentary on Netflix, you may soon be getting a sequel. The documentary’s writer, Donick Cary, recently revealed that a series or film — or both — is on the horizon, hinting at the possibility of a podcast as well.
The “Adventures in Psychedelics” documentary first aired on Netflix in May 2020. However, it took more than a decade to make, with Mike Rosenstein, who was the producer, and Cary interviewing celebrities such as Anthony Bourdain, A$AP Rocky and Carrie Fisher about their experiences with psychedelics…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
University of Wisconsin-Madison Launches Psychedelics Research Center
At the start of the week, the School of Pharmacy at the University of Wisconsin-Madison unveiled its psychedelics center, named the Transdisciplinary Center for Research in Psychoactive Substances. Researchers will investigate the therapeutic potential of psychedelics like MDMA and psilocybin in treating conditions such as opioid addiction, major depressive disorder and post-traumatic stress disorder. In addition to this, the center will also offer educational training for psychedelics practitioners and scientists.
In its press release, the department asserted that the institute would work to consider diversity participants used in research, noting that people of color were often underrepresented in psychedelics studies…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Study Finds That Most Mental Health Service Users Support Psychedelics Research
A study that was recently published in the “Irish Journal of Medical Science” has found that individuals who use mental health services in Ireland favorably view research on psychedelics. The study found that more than half of its participants were willing to try psychedelic therapy if their physicians recommended it.
However, the study also found evidence of therapeutic misalignment as the symptoms of some individuals who suffer from mental health disorders could be worsened…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Microdose Psychedelic Insights Announces Upcoming DMT Conference
Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting next month’s DMT Conference. Held in an entirely virtual format, the conference is slated for Sept. 9–10, 2021. According to the announcement, the event will focus on the potential of dimethyltryptamine (“DMT”) regarding drug development and safety, clinical care, law and regulation, business and markets, science and research. The DMT conference is part of Microdose’s Molecular Masterclasses conference events, a speaker series designed for deep dives into the world’s favorite psychoactive and psychedelic substances. The informative DMT Conference is designed to provide insight and education into the space of DMT therapeutics and will feature expert panels and engaging discussions. The 2021 conference will feature a presentation by CEO of Microdose Psychedelic Insights Patrick Moher as well as a series of hourlong presentations and various keynote addresses. Topics to be covered will include “Addiction and DMT,” “Non-Neuropsychiatric Uses for DMT,” “DMT Drug Development,” and a keynote presentation by Algernon Pharmaceuticals titled “DMT — New Hope for Healing the Brain After a Stroke,” among others. Conference presenters include Christopher Timmermann-Slater, Andrew Hegle, Paul Van Slyke, Daniel Cohen, Christopher Moreau, Jackie von Salm, Carol Routledge, Brian Jahns, Natan Ponieman, Andrew Hegle Paul Van Slyke, Peter Rands, Graham Pechenik, David Wood, Ruth Chun, Hadas Alterman, Rick Strassman, Timothy Ko, Brian Jahns, Crystal Carson, Joël Brierre, Max Montrose, Tricia Eastman, Rak Razam, and Victoria Wueschner among others.
To attend the full conference, visit https://ibn.fm/7TbOg
To view the full press release, visit https://ibn.fm/MNUgQ
About Microdose Psychedelic Insights
Microdose Psychedelic Insights is a guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, the company distribute and create the most compelling content, financial analysis, engaging events, and ground-breaking education to drive the psychedelics industry to the forefront of modern medicine. For more information about the company, visit www.Microdose.buzz.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Positioned as First Mover in Psychedelics Space
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was recently hosted by Oren Klaff on the Dealmaker Podcast. The interview, which illuminated Tryp Therapeutics’ operations and McKee’s personal story on how he ended up as the CEO, offered some great insights into the future of the psychedelics space, along with what ordinary people can do to take the industry to the next level. A recent article reads, “Mr. McKee cited the benefits that come with the use of psilocybin in treating pain. For one, he discussed their effectiveness without the accompanying risk of addiction associated with opioids. He also acknowledged that psychedelics are far from mainstream, but that is an opportunity for the company to play the role of a first mover. ‘They [psychedelics] are not mainstream yet. That’s actually the opportunity. Nobody’s done that yet. We’re just now making them synthetically and making them up to pharmaceutical-grade standards,’ Mr. McKee noted.”
To view the full article, visit https://ibn.fm/crzSJ
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio
- Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs
- Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions
- Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically covers the psychedelic renaissance and digs deeper into what has happened to the psychedelic industry from 2017 to 2020. The two-part series captures key moments in the history of the psychedelic sector, as well as providing a brief outline of those events and the state of the industry. “The industry has firmly established credibility and is becoming better known for therapeutic practices rather than recreational use, differentiating it from other sectors such as cannabis,” the content states. “Although the challenges of the nascent psychedelics industry are often compared to the cannabis industry, the two are significantly different. The next chapter in the psychedelics story will center around biotechnology, new drug discoveries, and the many unknown applications of each of these substances.”
To view the full release, visit https://ibn.fm/y9Pxz
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance
- Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes
- The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics
- The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry
- Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder
Portland Activists Call for Psychedelics to Be Decriminalized
Activists in Portland are calling for the city commission to approve a measure that would decriminalize the ceremonial use, gifting and growing of a number of psychedelics. This new measure would make community-based ceremonies and activities that involve entheogenic substances such as ibogaine and ayahuasca among the lowest law-enforcement priorities in Portland, Oregon.
The activists, who are part of the PMHA (Plant Medicine Healing Alliance), worked with indigenous groups to draw up the initiative…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” an article quoted Cybin CEO Doug Drysdale discussing the milestone. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.” Drysdale noted that expanded access to investors is expected to further fuel Cybin’s mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.
To view the full article, visit https://ibn.fm/aqlK8
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
What To Know Before Investing in the Psychedelic Industry
The burgeoning marijuana industry has presented numerous investment opportunities for individuals and companies alike. The psychedelic drug market, which is still immature, seems to be following this trend, with projections showing that its market size will have reached almost $11 billion by 2027.
Most analysts agreewith a capital markets analyst from Canaccord Genuity, who estimates that psychedelic substances such as LSD and psilocybin could create an investment opportunity worth nearly $100 billion…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Appoints Members to Newly Formed Medical Advisory Board
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has created a Medical Advisory Board to advise the company and its subsidiaries in developing safety protocols and best practices. Board members include an impressive array of medical professionals including a neuroscientist, anesthesiologist, addiction psychiatrist, interventional pain physician and more. These board members were carefully appointed to serve as thought leaders and advisors. The board will serve as an invaluable resource for Delic as it focuses on developing psychedelic wellness treatments today as well as looking toward the future. In addition, board members will be a resource for media, other medical associates and general audiences interested in the science behind psychedelic wellness and treatments. Initial board members include Dr Matthew Cook, MD, president and founder of BioReset(TM) Medical and a medical advisor to BioReset Network; Dr. David Rabin, MD, PhD, a board certified psychiatrist and neuroscientist as well as co-founder and chief innovation officer of Apollo Neuroscience and co-founder and executive director of The Board of Medicine; Dr. Iru Gerard Fernando, MD,a board certified general and addiction psychiatrist as well as the medical director of addiction services at Psychiatric Wellness Center and division medical director for Aspire Behavioral Health; Dr. Chris Ray, PhD, and interventional pain physician; Yessica Avancena, MFT, MBA, a certified mindfulness teacher (“CMT”), psychotherapist and entrepreneur; and Barbara Branaman, the co-founder and CEO of the suite of BioReset brands, products and services, including BioReset University. “Science and medicine are the basis of Delic’s approach to psychedelic wellness and our experienced and diverse Medical Advisory Board will help ensure our commitment to safety, quality and efficacy of treatments,” said Delic CEO Matt Stang in the press release. “This impressive group represents well-known leaders in the psychedelic and addiction fields and will help usher in a greater understanding of the science and data behind what we expect to be the most effective treatments for many mental health conditions ever available.”
To view the full press release, visit https://ibn.fm/d231D
About Delic Corp Inc.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms such as Reality Sandwich; Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Psychedelic Clinical Trials in Europe to Advance Through Partnership with CROs
A new dawn in psychedelic research seems to be upon the pharmaceutical industry as we are witnessing partnerships between drug-development companies and contract research organizations. The partnerships are intended to speed up the drug-development process.
For example, a partnership between Transpharmation and Clerkenwell Health will facilitate the advancement of psychedelic research in Europe as it will enable both clinical and preclinical trials to run simultaneously...
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Four Fungi Facts Revealed by Netflix Psychedelics Documentary
Psychedelics have become increasingly popular in the last few years as more studies on the substances are conducted by research institutions around the world. The most popular of these substances are LSD, MDMA and psilocybin mushrooms. If you’re yearning to know more about these substances and mushrooms and other fungi in general, but aren’t keen on reading papers in peer review journals, Netflix may be of use to you. The subscription-based streaming service has a documentary, titled “Fantastic Fungi.” that talks about different fungi,
The documentary reveals interesting things about mushrooms, some of which aren’t commonly known. For instance, did you know that mushrooms:
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF) Meet Delic Event to Feature Award-Winning Investigative Reporter as Keynote Speaker
Delic Corp Inc. (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced one of its headline speakers for its upcoming Meet Delic event. Award-winning investigative reporter Ben Westhoff will present a keynote address titled “Fentanyl in Our Drugs,” which will discuss how fentanyl is upending the entire recreational drug landscape. His presentation includes a look at how fentanyl impacts drug-legalization prospects, dark-web markets, geopolitics and much more. Westhoff focuses his reporting on culture, drugs and poverty, and his book, titled “Fentanyl, Inc.: How Rogue Chemists Created the Deadliest Wave of the Opioid Epidemic” has been called a bombshell book about the fentanyl epidemic. He has written for “The Atlantic,” “The Wall Street Journal,” “Rolling Stone” and “The Guardian.” Delic Corp. presents Meet Delic, which is a two-day immersive edutainment experience for the world’s leading psychedelic and wellness thought and business leaders. The two-day event is scheduled for Nov. 6–7, 2021, in Las Vegas.“Ben’s thought-provoking journalism has exposed serious problems with the way we fight drug abuse and opens up the possibility of better treatment with far fewer side effects,” said Delic co-founder Jackee Stang in the press release. “His objective take on the realm of treatments will be incredibly interesting and educational for the Meet Delic audience.”
To register for the event, visit https://ibn.fm/BujPn
To view the full press release, visit https://ibn.fm/tpgec
About Delic Corp Inc.
Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms such as Reality Sandwich; Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Psychotherapy Training for Upcoming Clinical Trial
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced it has completed the training of psychotherapists for its upcoming phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. According to the update, the training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals administering psychedelic compounds to patients. “We continue to be amazed by the complexity of neural networks and the array of biological and behavioral factors that influence the healthy functioning of the brain and body,” said Jim Gilligan, Ph.D., president and chief science officer of Tryp Therapeutics. “Our partners at the University of Florida have shown tremendous commitment to the effective administration of psychotherapy for our upcoming phase 2a clinical trial, and Fluence continues to be an exceptional partner for the design and implementation of this important component of our therapies. The completion of this psychotherapy training marks a significant milestone for Tryp, as it remains an integral part of our novel treatment.”
To view the full press release, visit https://ibn.fm/s1H8B
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Five Medical Benefits of Psychedelics
Research on psychedelics has found that the substances could be effectively used to treat various mental health conditions, including post-traumatic stress disorder and anxiety. But, what other therapeutic and medical benefits do psychedelics possess that may help humanity?
Making organ transplants safer
Ischemia-reperfusion injury, commonly referred to as IRI, occurs when organ tissues are damaged after being deprived of oxygen for some time…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report
- Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange
- Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO
- Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp delves into the evolution of psychedelics from an ancient antidote “to breakthrough medicine with massive therapeutic potential for a wide range of notoriously hard-to-treat diseases.” “With these strict legal changes around the world, the psychedelics industry became largely inactive. But today, an explosion of unprecedented research findings surrounding the therapeutic potential of psychedelics has triggered many countries to reassess their decision to criminalize,” the publication reads. “Now, the industry is back, and bigger than ever before. In Part 2 of The History of Psychedelics, we’ll dive into The Psychedelics Renaissance the industry is currently experiencing and discuss the exciting future of this promising sector.”
To view the full article, visit https://ibn.fm/5LEsj
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain chronic pain and eating disorder indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Salvia Divinorum: The Less-Known Psychedelic and Its Properties
The popularity of psychedelics has been growing as the research conducted on these substances for their therapeutic benefits increases. Substances such as DMT, LSD, MDMA and psilocybin are the most studied as well as the most common psychedelics while others, including salvia divinorum, aren’t popularly known.
Salvia divinorum is a psychoactive plant used in rituals in Mazatec shamanic ceremonies. The plant species is found in the mountainous Sierra Mazateca area near Mexico’s Oaxaca City…
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Florida Researchers Seek Answers on Ability of Psychedelics to Treat Psychological Conditions
Research on psychedelic substances and the therapeutic properties they possess that can be used to treat various mental health conditions has been increasing. For example, researchers in Florida are focused on studying psilocybin, which is the active compound found in magic mushrooms.
Earlier in 2019, the FDA granted breakthrough therapy status to psilocybin treatments under development, which made it easier for the Usona Institute, a nonprofit organization, to conduct studies on the psychedelic…
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’
- Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research
- The Vancouver-based company was formed in 2019 as the first psychedelic umbrella platform
- The Delic self-sustaining Ecosystem covers three main areas: media, health, and science
- On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company, a legacy counterculture distributor of psychedelic media
- An estimated $238 billion is spent annually in the U.S. on mental health treatments and ancillary services
- University-led and FDA-approved studies are positioning North America as a leading region in the advancement of psychedelics for therapeutic, medical, and recreational use
Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones
- Cybin subsidiary achieved certain milestones as outlined in acquisition agreement
- Adelia brought numerous advantages to company
- Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files Two International Patent Applications in Support of the Company’s Research Phase Programs
Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibility for CYBN to obtain patent coverage in 153 countries and, if approved, allow the company to file future national applications into treaty member jurisdictions. The company filed the applications under the Patent Cooperation Treaty (“PCT”). One of the patent applications concerns a group of proprietary compounds that the company has identified as important for further evaluation toward selection as potential therapeutics. The other application regards claims and disclosures toward other proprietary novel psychedelic compounds, including compounds with positive research data, that meet the company’s internal research metrics. Cybin asserts that these applications will strengthen its CYB005 program and provide compositions for additional evaluation in future research programs. “Cybin is dedicated to finding treatments for therapy resistant psychiatric indications as we believe these will provide patients and their medical providers with new avenues to address this significant unmet need. We appreciate the continued dedication of our team to identify and progress our research phase programs toward pre-clinical evaluation,” said Cybin CEO Doug Drysdale in the press release.
To view the full press release, visit https://ibn.fm/kmKVM
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.